Lighthouse Investment Partners LLC Invests $1.08 Million in Hologic, Inc. (NASDAQ:HOLX)

Lighthouse Investment Partners LLC acquired a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 15,000 shares of the medical equipment provider's stock, valued at approximately $1,081,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Venturi Wealth Management LLC lifted its stake in shares of Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 159 shares during the period. Smithfield Trust Co raised its stake in Hologic by 160.0% during the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after buying an additional 400 shares during the period. Finally, Sound Income Strategies LLC acquired a new position in Hologic during the 4th quarter worth approximately $60,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HOLX has been the topic of a number of research reports. StockNews.com downgraded Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research note on Friday, May 2nd. Leerink Partnrs downgraded Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Stephens dropped their price target on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Finally, William Blair reaffirmed an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Twelve investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Hologic currently has a consensus rating of "Hold" and an average price target of $77.42.

Hologic Stock Up 0.4%

Shares of HOLX traded up $0.20 during mid-day trading on Tuesday, reaching $56.63. The company had a trading volume of 467,285 shares, compared to its average volume of 2,118,392. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The firm has a 50-day moving average price of $58.67 and a 200 day moving average price of $67.14. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.67. The company has a market capitalization of $12.62 billion, a price-to-earnings ratio of 17.90, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. During the same period in the previous year, the firm posted $1.03 EPS. The business's revenue for the quarter was down 1.2% compared to the same quarter last year. On average, sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Buying and Selling at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of the firm's stock in a transaction on Wednesday, May 7th. The stock was acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the purchase, the director now owns 5,445 shares in the company, valued at approximately $300,781.80. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.88% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.